INTRODUCTION:
The purpose of our study is to identify maternal characteristics that are associated with increased likelihood of placenta previa persisting to delivery.
METHODS:
We performed a retrospective, cohort study of 695 women diagnosed with placenta previa between 17 and 24 weeks gestation, who delivered at a Geisinger Health System facility from 2002 to 2016. Variables of interest included age, BMI, race, smoking status, substance abuse, parity, multigravida status, history of cesarean section, history of dilation and curettage, and history of placenta previa in prior a pregnancy. Logistic regression techniques were used for statistical analysis, P-values <0.05 considered significant.
RESULTS:
Of the 695 cases of placenta previa reviewed, a total of 368 cases were deemed complete placenta previa and the remaining cases were low-lying placentas. A total 63 (17.1%) women with complete placenta previa in the second trimester persisted to 36 weeks 0/7 days gestation requiring cesarean section. In the women diagnosed initially with complete placenta previa, a history of cesarean section (P<.001), history of dilation and curettage (P=.004), and multigravida (P<.001) were statistically significant, univariately. Other variables of interest were found not to be statistically significant. In a multivariate regression model, history of cesarean section and history of dilation and curettage remained significant with odds of persistent placenta previa (PPP) 7.0 (95% CI 3.72-13.07) and 2.5 (95% CI 1.27-5.01), respectively.
CONCLUSION:
Women diagnosed with complete placenta previa in the second trimester with a history of cesarean section and dilation and curettage are significantly more likely to have PPP.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.